Scientific Programme
Wednesday, 21 September 2016 |
12:00 – 14:30 Registration |
Plenary Session 1 (Ballroom) 14:30 – 14:45 ESCMID introductory lecture. Mario Poljak, ESCMID President 14:45 – 15:15 AMR: a global challenge. Barbara Murray |
Symposium 1 (Ballroom) New chemical space: where are new antibiotics coming from? Chair: Tom Parr 15:15 – 15:45 Antibiotics do not necessarily obey Lipinski's rules. Matt Cooper 15:45 – 16:15 Discovering new antibiotics in nature. Heike Brötz-Osterhelt 16:15 – 16:45 Why target-based drug discovery has not been very successful. Steve Baker 16:45 – 17:15 Getting drugs into Gram-negative bacteria. Mathias Winterhalter |
17:30 – 19:00 Welcome reception at the venue (Parkhotel Schönbrunn) |
Thursday, 22 September 2016Plenary Session 2 (Ballroom) 08:00 – 08:30 Drug development within the context of AMR: giving new molecules the best chance. John Rex Symposium 2 (Ballroom) Recent advances in regulation to meet the challenge of AMR Chair: Christa Wirthumer-Hoche 08:30 – 09:00 FDA. Ed Cox 09:00 – 09:30 EMA. Marco Cavaleri 09:30 – 10:00 Common regulatory issues for drug development programmes. Mair Powell 10:00 – 10:30 Coffee Break Symposium 3 (Ballroom) In-vitro susceptibility testing and establishing breakpoints for new compounds Chair: Alasdair MacGowan 10:30 – 11:00 Current tools and approaches for setting breakpoints. Johan Mouton 11:00 – 11:30 Global harmonization of breakpoints – can it be achieved? Gunnar Kahlmeter 11:30 – 12:00 Regulatory issues around test development and validation. Ron Jones 12:00 – 12:30 MIC wild type distributions and ECOFFs and their role in setting clinical breakpoints. John Turnidge 12:30 – 13:30 Lunch Symposium 4 (Ballroom) Developing new drugs for AMR in special populations Chair: Mike Sharland 13:30 – 14:00 Pharmacometrics for special populations. Johannes Van den Anker 14:00 – 14:30 Challenges in developing drugs for critical illness. Jean Chastre 14:30 – 15:00 Addressing therapeutic challenges of AMR in neonates. John Bradley 15:00 – 15:30 Approaches for defining safe and effective regimens for children. Mike Sharland 15:30 – 16:00 Coffee Break Symposium 5 (Ballroom) Getting AMR research funded Chair: Keith Rodvold 16:00 – 16:30 Overview of the current efforts. Herman Goossen 16:30 – 17:00 From big pharma to small and back again. Karen Shaw 17:00 – 18:00 Round table: resources for antibiotic drug discovery. Moderator: David Hooper – MRC. Jonathan Pearce – BARDA. Christopher Houchens – NIH. Francois Franceschi 18:45 – 23:00 Networking dinner: Weinhof Zimmermann Mitterwurzergasse 20 1190 Wien www.weinhof-zimmermann.at |
Friday, 23 September 2016Plenary Session 3 (Ballroom) 08:00 – 08:30 Drug discovery within the context of AMR: extending beyond ‘me too’ drugs. Tom Parr Symposium 6 (Ballroom) Techniques for accelerating and de-risking drug development Chair: William Hope 08:30 – 09:00 Utilizing PK/PD to increase the probability of successful drug development. Paul Ambrose 09:00 – 09:30 Strength and limitations of pre-clinical models for drug development. Sujata Bhavnani 09:30 – 10:00 Developments in PK/PD modelling and approaches: what to do when the standard model does not describe the data. Elisabet Nielsen 10:00 – 10:30 PK/PD to decrease the development of drug resistance in new molecules. Arnold Louie 10:30 – 11:00 Coffee Break Symposium 7 (Ballroom) Innovative clinical trial design for AMR Chair: Stephan Harbarth 11:00 – 11:30 Real world challenges in performing clinical trials for drug resistant disease. Steve Projan 11:30 – 12:00 Developing drugs in combination. Mike Dudley 12:00 – 12:30 Debate: PK/PD versus frequentist approaches for drug development – Pro. Tom Lodise 12:30 – 13:00 Debate: PK/PD versus frequentist approaches for drug development – Con. Dean Follmann 13:00 – 14:00 Lunch Interactive Session (Ballroom) 14:00 – 15:00 Interactive Session: Bring questions about your own molecule! Expert panel: - George Drusano, Institute for Therapeutic Innovation, University of Florida (Lake Nona, US) - Mike Dudley, The Medicines Company (San Diego, US) - Arnold Louie, University of Florida, College of Medicine (Orlando, US) - Tom Parr, Spero Therapeutics (Cambridge, US) - David Perlin, Rutgers New Jersey Medical School (Newark, US) - Ursula Theuretzbacher, Center for Anti-Infective Agents (Vienna, AT) |
You can submit questions for the expert panel HERE. |
15:00 – 15:15 Conclusion and closing of the conference (Ballroom) |
CME Accreditation
The conference was granted 13 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).